Product Description
Mechanisms of Action: STAT3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sumitomo Dainippon Pharma Co
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Brazil, Canada, Estonia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Lithuania, Poland, Romania, Russia, Spain, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STEMNESS-PANC | P3 |
Unknown Status |
Pancreatic Cancer|Adenocarcinoma |
2026-03-31 |
|
| STEMNESS-CRC | P3 |
Unknown Status |
Adenocarcinoma|Colorectal Cancer |
2025-09-30 |
|
| 2020-000613-32 | P3 |
Active, not recruiting |
Colorectal Cancer|Adenocarcinoma |
2024-02-24 |
|
| 2019-002553-35 | P3 |
Active, not recruiting |
Adenocarcinoma|Pancreatic Cancer |
2022-10-21 |